INCY.O (INCY.O) News
Track canonical SquawkNews coverage tagged to INCY.O, INCY.O. This hub brings together deduplicated headlines about market instrument, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 2 indexed stories across 1 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
Mirum, Incyte say FDA approves Atebrioz for FOP patients
The FDA approved Atebrioz (zilurgisertib) tablets for adult and pediatric patients aged 12 years and older with fibrodysplasia ossificans progressiva. The companies said the treatment will be available in the U.S. in Oct
EQUITY | Sep 25, 2026, 11:00 PM UTC
L
FDA approves Atebrioz for fibrodysplasia ossificans progressiva in adults, pediatric patients
FDA says Atebrioz (zilurgisertib) is approved for fibrodysplasia ossificans progressiva in adults and pediatric patients 12 years and older. The recommended dosage is 100 mg once daily.
REGULATION | Sep 25, 2026, 09:50 PM UTC